Results 41 to 50 of about 432,986 (215)

Focal Segmental Glomerulosclerosis [PDF]

open access: yes, 2011
Focal segmental glomerulosclerosis accounts for approximately 20% of cases of the nephrotic syndrome in children and 40% of such cases in adults, with an estimated incidence of 7 per 1 million.(1) It is the most common primary glomerular disorder causing
Kaskel, Frederick   +2 more
core   +1 more source

A Case of Focal Segmental Glomerulosclerosis in Turner Syndrome [PDF]

open access: yesKosin Medical Journal, 2015
Turner syndrome is usually accompanied with various anomalies. Congenital urological and renal abnormalities are often associated with this syndrome. The occurrence of glomerulonephritis is uncommon.
A Rum Han   +5 more
doaj   +1 more source

Podocyte-specific Crb2 knockout mice develop focal segmental glomerulosclerosis

open access: yesScientific Reports, 2021
Crb2 is a cell polarity-related type I transmembrane protein expressed in the apical membrane of podocytes. Knockdown of crb2 causes glomerular permeability defects in zebrafish, and its complete knockout causes embryonic lethality in mice.
A. Tanoue   +12 more
semanticscholar   +1 more source

APOL1 Risk Alleles Are Associated With More Severe Arteriosclerosis in Renal Resistance Vessels With Aging and Hypertension

open access: yesKidney International Reports, 2016
The increased risk of end-stage kidney disease among hypertensive African Americans is partly related to APOL1 allele variants. The initial glomerulosclerosis of hypertension-associated arterionephrosclerosis consists of focal global glomerulosclerosis ...
Michael D. Hughson   +6 more
doaj   +1 more source

Cyclophosphamide in the treatment of focal segmental glomerulosclerosis [PDF]

open access: yesBrazilian Journal of Medical and Biological Research, 2004
Prednisone is the initial treatment of primary focal segmental glomerulosclerosis. However, when immunosuppressive agents in combination with steroids are used in the treatment of prednisone-dependent and prednisone-resistant patients the remission rate ...
R. Martinelli   +4 more
doaj   +1 more source

Collapsing glomerulopathy in sickle cell disease: a case report

open access: yesJournal of Medical Case Reports, 2011
Introduction Sickle cell disease has been associated with many renal structural and functional abnormalities. Collapsing glomerulopathy or the collapsing variant of focal segmental glomerulosclerosis is a rare clinicopathologic entity in patients with ...
Sealy Peter L   +2 more
doaj   +1 more source

Soluble urokinase plasminogen activator receptor (suPAR) and glomerular disease in children: a narrative review

open access: yesEgyptian Pediatric Association Gazette, 2022
Background Focal segmental glomerulosclerosis (FSGS) is a chronic glomerular disease that responds poorly to treatment, with a large proportion of patients progressing to end-stage renal disease in spite of initial aggressive treatment.
Phuong Anh Le Thy   +3 more
doaj   +1 more source

Spectrum of disease in familial focal and segmental glomerulosclerosis [PDF]

open access: yes, 1999
Spectrum of disease in familial focal and segmental glomerulosclerosisBackgroundFocal segmental glomerulosclerosis (FSGS) is the underlying pathologic entity in 5% of adults and 20% of children with end-stage renal disease (ESRD).
Winn, Michelle P.   +12 more
core   +1 more source

Focal segmental glomerulosclerosis: Cellular variant and beyond [PDF]

open access: yes, 2006
The entity of focal segmental glomerulosclerosis (FSGS), oddly, includes several distinct changes involving glomeruli that need not be focal, segmental, or even sclerotic.
Nair, R.
core   +1 more source

Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis

open access: yesBMC Nephrology, 2020
Background Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited.
P. Hansrivijit   +3 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy